{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T09:12:05Z","timestamp":1790327525304,"version":"4.1.0"},"reference-count":180,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82570277"],"award-info":[{"award-number":["82570277"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical &amp; Translational Med"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:label\/>\n                    <jats:p>To date, the treatment of acute myeloid leukaemia (AML) remains a major challenge in hematologic malignancies, particularly among elderly patients who are unfit for intensive chemotherapy. Venetoclax, a BCL\u20102 inhibitor, in combination with azacitidine, has significantly improved the prognosis and survival of this patient population. However, approximately 30% of patients do not respond to venetoclax\u2010based combination regimens, and most initial responders eventually experience relapse. Therefore, resistance to venetoclax has become a critical bottleneck limiting its long\u2010term clinical benefits. A thorough understanding of the underlying resistance mechanisms and the development of novel strategies to overcome resistance are central to improving survival outcomes in elderly AML patients. The resistance mechanisms of venetoclax are complex and multifaceted, including genetic drivers such as TP53 mutations, FLT3\u2010ITD, and NRAS\/KRAS mutations, as well as the upregulation of anti\u2010apoptotic proteins (e.g., MCL\u20101, BCL\u2010xL), metabolic reprogramming, and altered cellular differentiation states. In response to these factors, emerging therapeutic strategies are rapidly evolving toward precision\u2010based and combination approaches, including combinations with targeted agents (e.g., IDH2 inhibitors, FLT3 inhibitors), MCL\u20101 inhibitors, optimization of current dosing regimens (e.g., DEC3\u2010VEN), and the development of novel modalities (e.g., antibody\u2010drug conjugates, CAR\u2010T cell therapy). Focusing on the disease characteristics of elderly AML, this narrative review summarizes the clinical efficacy of venetoclax, critically examines the multifaceted mechanisms of venetoclax resistance, and discusses current and emerging therapeutic strategies to overcome this resistance. The goal is to inform clinical practice and guide future translational research.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>This review elucidates the current mechanism of action, therapeutic effects, and limitations of venetoclax, focusing on its use and combination regimens in the specific patient population of elderly individuals with AML who are not suitable for intensive therapy, as well as strategies to overcome resistance, and provides future perspectives for addressing venetoclax resistance.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ctm2.70797","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T07:01:25Z","timestamp":1787900485000},"source":"Crossref","is-referenced-by-count":0,"title":["Venetoclax for elderly patients with acute myeloid leukaemia unfit for intensive chemotherapy: Prospects, resistance mechanisms and management strategies"],"prefix":"10.1002","volume":"16","author":[{"given":"Jinlin","family":"Zhang","sequence":"first","affiliation":[{"name":"First Central Hospital of Tianjin Medical University Tianjin Medical University  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jile","family":"Liu","sequence":"additional","affiliation":[{"name":"First Central Hospital of Tianjin Medical University Tianjin Medical University  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohan","family":"Zhao","sequence":"additional","affiliation":[{"name":"First Central Hospital of Tianjin Medical University Tianjin Medical University  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Zhang","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College Shandong Medical and Pharmaceutical University  Shandong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Liu","sequence":"additional","affiliation":[{"name":"First Central Hospital of Tianjin Medical University Tianjin Medical University  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengnan","family":"Li","sequence":"additional","affiliation":[{"name":"School of Medicine Nankai University  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changze","family":"Cao","sequence":"additional","affiliation":[{"name":"First Central Hospital of Tianjin Medical University Tianjin Medical University  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6605-2458","authenticated-orcid":false,"given":"Rui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology Tianjin First Central Hospital Tianjin Thrombosis and Hemostasis Institute  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5995-7558","authenticated-orcid":false,"given":"Mingfeng","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Hematology Tianjin First Central Hospital Tianjin Thrombosis and Hemostasis Institute  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01389-4"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2025.168065"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14082759"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.303"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025017934"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1577908"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025017083"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27655"},{"issue":"9","key":"e_1_2_10_10_1","first-page":"988","article-title":"Venetoclax resistance and molecular abnormalities in AML","volume":"66","author":"Nagata Y","year":"2025","journal-title":"Rinsho ketsueki"},{"key":"e_1_2_10_11_1","article-title":"Longitudinal single\u2010cell atlas of therapy\u2010induced bone marrow microenvironment remodeling in AML","volume":"628","author":"Lu H","year":"2025","journal-title":"Cancer Lett"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025028651"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971"},{"key":"e_1_2_10_14_1","unstructured":"American Society of Hematology Venetoclax Combination Granted Full Approval for Newly Diagnosed AML ASH Clinical News 2021."},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00672-y"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02730-3"},{"issue":"6","key":"e_1_2_10_17_1","first-page":"e142","article-title":"Real\u2010world outcomes with venetoclax plus azacitidine in acute myeloid leukemia: impact of infectious complications on survival","volume":"98","author":"Lindsley RC","year":"2023","journal-title":"Am J Hematol"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2023.2293512"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2024.101238"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2025.2604566"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-46"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bglo.2025.100045"},{"issue":"3","key":"e_1_2_10_23_1","first-page":"149","article-title":"Efficacy and safety analysis of venetoclax combined with azacitidine regimen for treatment of newly diagnosed elderly patients with AML","volume":"34","author":"Chen X","year":"2025","journal-title":"Leuk Lymphoma"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-6411"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-868752"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00770-x"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33814"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-025-04093-y"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000968612.00896.64"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2024.100038"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.113979"},{"issue":"12","key":"e_1_2_10_32_1","first-page":"636","article-title":"Clinical study of venetoclax combined with hypomethylating drugs for the treatment of acute myeloid leukemia","volume":"50","author":"Yan LJ","year":"2023","journal-title":"Chinese J Clin Oncol"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/15384101.2025.2484868"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms27021123"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2008.37"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2009.39"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4419-6706-0_3"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymeth.2013.03.030"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-023-00629-4"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04810-z"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-0939"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2012.12.011"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergencyto.2010.09.002"},{"key":"e_1_2_10_44_1","first-page":"191","volume-title":"Current Topics in Microbiology and Immunology","author":"Croce CM","year":"2017"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbior.2018.12.002"},{"issue":"8","key":"e_1_2_10_46_1","first-page":"440","article-title":"Venetoclax, the first BCL\u20102 inhibitor for use in patients with chronic lymphocytic leukemia","volume":"17","author":"Seymour JF","year":"2019","journal-title":"Clin Adv Hematol Oncol"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2129-0"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.553"},{"issue":"1","key":"e_1_2_10_49_1","first-page":"89","article-title":"Targeting BCL2 with BH3 mimetics: basic science and clinical application of venetoclax in chronic lymphocytic leukemia and related B cell malignancies","volume":"101","author":"Anderson MA","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-344812"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-387399"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025029875"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1910685"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-1297"},{"key":"e_1_2_10_55_1","unstructured":"YoshidaA. Molecular targeted therapy against leukemia stem cells via inhibition of anti\u2010apoptotic proteins. KAKEN: grants\u2010in\u2010aid for scientific research;2016."},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-212302"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009081"},{"key":"e_1_2_10_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.70139"},{"key":"e_1_2_10_59_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1386517"},{"key":"e_1_2_10_60_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-23-0344"},{"key":"e_1_2_10_61_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-14998-w"},{"key":"e_1_2_10_62_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-025-06543-3"},{"key":"e_1_2_10_63_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3274"},{"key":"e_1_2_10_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2025.01.024"},{"key":"e_1_2_10_65_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25010484"},{"key":"e_1_2_10_66_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.28091"},{"key":"e_1_2_10_67_1","unstructured":"RahmaniM. Therapeutic targeting of p53 reactivation\u2010induced OXPHOS dependency and stress responses to overcome resistance to venetoclax\/HMA in AML. HHS TAGGS: award information;2022."},{"key":"e_1_2_10_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2024.100016"},{"key":"e_1_2_10_69_1","doi-asserted-by":"publisher","DOI":"10.1159\/000548334"},{"key":"e_1_2_10_70_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01189-2"},{"key":"e_1_2_10_71_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-3450"},{"key":"e_1_2_10_72_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.222588"},{"key":"e_1_2_10_73_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1119"},{"issue":"1","key":"e_1_2_10_74_1","first-page":"45","article-title":"BAX dependency of venetoclax response in TP53\u2010mutated acute myeloid leukemia","volume":"13","author":"Zhang H","year":"2023","journal-title":"Blood Cancer J"},{"issue":"4","key":"e_1_2_10_75_1","first-page":"1123","article-title":"Synthetic lethality of combined Bcl\u20102 and Mcl\u20101 inhibition in TP53\u2010mutated acute myeloid leukemia","volume":"15","author":"Pan R","year":"2023","journal-title":"Cancers"},{"key":"e_1_2_10_76_1","article-title":"Mechanisms of venetoclax resistance in acute myeloid leukemia: from bench to bedside","volume":"15","author":"DiNardo CD","year":"2025","journal-title":"Front Oncol"},{"issue":"5","key":"e_1_2_10_77_1","first-page":"412","article-title":"Genetic factors determining sensitivity to venetoclax in acute myeloid leukemia","volume":"65","author":"Yamaguchi H","year":"2024","journal-title":"Rinsho ketsueki"},{"key":"e_1_2_10_78_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-186907"},{"key":"e_1_2_10_79_1","unstructured":"MamdouhAM LimFQ MiY et\u00a0al.Targetable BIRC5 dependency in therapy\u2010resistant TP53 mutated acute myeloid leukemia[preprint]. bioRxiv.2025."},{"key":"e_1_2_10_80_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.70344"},{"key":"e_1_2_10_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101585"},{"key":"e_1_2_10_82_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08137-x"},{"issue":"1","key":"e_1_2_10_83_1","first-page":"578","article-title":"Outcomes with low\u2010intensity venetoclax in NPM1\u2010mutated AML depend on co\u2010mutational profile [Abstract]","volume":"144","author":"Lachowiez CA","year":"2024","journal-title":"Blood"},{"key":"e_1_2_10_84_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-995"},{"key":"e_1_2_10_85_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-453"},{"key":"e_1_2_10_86_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17091586"},{"key":"e_1_2_10_87_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06810-7"},{"key":"e_1_2_10_88_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0341461"},{"issue":"3","key":"e_1_2_10_89_1","first-page":"621","article-title":"Establishment and mechanistic study of venetoclax\u2010resistant cell lines in acute myeloid leukemia","volume":"33","author":"Liu KF","year":"2025","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"e_1_2_10_90_1","unstructured":"ChakrabortyS MorgantiC Rivera PenaB et\u00a0al.A STAT3 degrader demonstrates pre\u2010clinical efficacy in venetoclax resistant acute myeloid leukemia[preprint]. bioRxiv.2024."},{"key":"e_1_2_10_91_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00870-3"},{"key":"e_1_2_10_92_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19314"},{"key":"e_1_2_10_93_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02694-4"},{"key":"e_1_2_10_94_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature08646"},{"key":"e_1_2_10_95_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-605584"},{"key":"e_1_2_10_96_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abo6891"},{"key":"e_1_2_10_97_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.260331"},{"key":"e_1_2_10_98_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S194549"},{"key":"e_1_2_10_99_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3279"},{"key":"e_1_2_10_100_1","doi-asserted-by":"publisher","DOI":"10.1002\/adbi.202500710"},{"key":"e_1_2_10_101_1","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-24-0256"},{"key":"e_1_2_10_102_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011475"},{"key":"e_1_2_10_103_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-179527"},{"key":"e_1_2_10_104_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024028239"},{"key":"e_1_2_10_105_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1005659"},{"key":"e_1_2_10_106_1","doi-asserted-by":"publisher","DOI":"10.3390\/clinbioenerg2010001"},{"key":"e_1_2_10_107_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.6537"},{"key":"e_1_2_10_108_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.659253"},{"issue":"22","key":"e_1_2_10_109_1","first-page":"1922","article-title":"Mechanisms of resistance to venetoclax in hematologic malignancies","volume":"13","author":"Zielonka K","year":"2024","journal-title":"Cells"},{"key":"e_1_2_10_110_1","volume-title":"Metabolic Mechanisms of Venetoclax Resistance in Acute Myeloid Leukemia Stem Cells","author":"Jordan CT","year":"2019"},{"issue":"22","key":"e_1_2_10_111_1","first-page":"3751","article-title":"Molecular pathways of leukemia resistance to treatment with venetoclax","volume":"30","author":"Yan JX","year":"2024","journal-title":"Int Med Health Guid News"},{"key":"e_1_2_10_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2025.01.165"},{"key":"e_1_2_10_113_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000974036.37075.c8"},{"issue":"3","key":"e_1_2_10_114_1","first-page":"of1","article-title":"Azacitidine, venetoclax, and magrolimab in newly diagnosed and relapsed refractory acute myeloid leukemia: phase Ib\/II study and correlative analysis","volume":"31","author":"Daver N","year":"2025","journal-title":"Clin Cancer Res"},{"key":"e_1_2_10_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(25)00254-6"},{"issue":"9","key":"e_1_2_10_116_1","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.3324\/haematol.2024.285014","article-title":"A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed\/refractory acute myeloid leukemia","volume":"109","author":"Murthy GSG","year":"2024","journal-title":"Haematologica"},{"key":"e_1_2_10_117_1","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2025.058"},{"key":"e_1_2_10_118_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01911"},{"key":"e_1_2_10_119_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-186699"},{"key":"e_1_2_10_120_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-199882"},{"key":"e_1_2_10_121_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-45"},{"issue":"1","key":"e_1_2_10_122_1","first-page":"213","article-title":"Targeting ADSS overcomes venetoclax resistance in TP53\u2010mutated acute myeloid leukemia","volume":"146","author":"He X","year":"2025","journal-title":"Blood"},{"key":"e_1_2_10_123_1","doi-asserted-by":"crossref","unstructured":"MamdouhAM OlesinskiEA LimFQ et\u00a0al.TP53 mutations drive therapy resistance via post\u2010mitochondrial caspase blockade. bioRxiv.2025.672283.","DOI":"10.1101\/2025.08.28.672283"},{"key":"e_1_2_10_124_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-021-00177-w"},{"key":"e_1_2_10_125_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.01.007"},{"key":"e_1_2_10_126_1","doi-asserted-by":"publisher","DOI":"10.1159\/000525566"},{"key":"e_1_2_10_127_1","doi-asserted-by":"crossref","unstructured":"PopescuB JonesMF PiaoM et\u00a0al.Multiselective RAS(ON) inhibition targets oncogenic RAS mutations and overcomes RAS\/MAPK\u2010mediated resistance to FLT3 and BCL2 inhibitors in acute myeloid leukemia. bioRxiv [preprint];2025.","DOI":"10.1101\/2025.06.10.658786"},{"key":"e_1_2_10_128_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00871-1"},{"key":"e_1_2_10_129_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.17274"},{"key":"e_1_2_10_130_1","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S429402"},{"issue":"1","key":"e_1_2_10_131_1","first-page":"1685","article-title":"Selinexor in combination with venetoclax and azacitidine for newly diagnosed (ND) unfit acute myeloid leukemia (AML): a multicenter, open\u2010label prospective study","volume":"146","author":"Wei A","year":"2023","journal-title":"Blood"},{"key":"e_1_2_10_132_1","unstructured":"HuX HuX WeiJ et\u00a0al. Selinexor combined with venetoclax maintenance therapy after allo\u2010HSCT. ClinicalTrials.gov identifier: NCT06765928. Ruijin Hospital Shanghai Jiao Tong University;2025."},{"key":"e_1_2_10_133_1","unstructured":"BallS SavonaMR MadanatY et\u00a0al. Phase Ib study of eltanexor and venetoclax in relapsed or refractory myelodysplastic syndrome and acute myeloid leukemia. ClinicalTrials.gov identifier: NCT06399640. Vanderbilt\u2010Ingram Cancer Center;2024."},{"key":"e_1_2_10_134_1","unstructured":"National Center for Biotechnology Information (US). PubChem Compound Summary for CID 73297272 Milademetan [Internet]. Bethesda (MD): National Library of Medicine (US); 2004 [cited 2026 May 26]. Available from:https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/73297272"},{"key":"e_1_2_10_135_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242115849"},{"key":"e_1_2_10_136_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.07.004"},{"key":"e_1_2_10_137_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-025-03825-8"},{"key":"e_1_2_10_138_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-04-638262"},{"key":"e_1_2_10_139_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-0028"},{"key":"e_1_2_10_140_1","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.70130"},{"key":"e_1_2_10_141_1","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70282"},{"key":"e_1_2_10_142_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-205980"},{"key":"e_1_2_10_143_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025029273"},{"key":"e_1_2_10_144_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027117"},{"key":"e_1_2_10_145_1","doi-asserted-by":"crossref","unstructured":"KadiaTM LeahyMF FlemingS et\u00a0al. Phase Ib\/II study of lisaftoclax (APG\u20102575) combined with azacitidine in patients with newly diagnosed or prior venetoclax\u2010exposed myeloid malignancies. ASH annual meeting; 2025 Dec 7\u201310; Orlando FL. Abstract 1641.","DOI":"10.1182\/blood-2025-1641"},{"issue":"22","key":"e_1_2_10_146_1","first-page":"3196","article-title":"Overcoming venetoclax resistance through heme\u2010mediated NOXA\/cyclin D1\/Mcl\u20101 axis with a novel artemisinin conjugate","volume":"9","author":"Zhang J","year":"2025","journal-title":"Blood Adv"},{"key":"e_1_2_10_147_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-1675"},{"key":"e_1_2_10_148_1","unstructured":"The First Affiliated Hospital of Soochow University. A prospective randomized open\u2010label study of venetoclax combined with azacitidine for consolidation therapy in adult acute myeloid leukemia [Internet]. ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US); 2026 Feb 23 [cited 2026 May 26]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT07425782"},{"key":"e_1_2_10_149_1","unstructured":"National Cancer Institute (US). Drug combo may target the unique metabolism of leukemia stem cells [Internet]. Cancer Currents Blog. 2018 Dec 14 [cited 2026 May26].Available from:https:\/\/www.cancer.gov\/news\u2010events\/cancer\u2010currents\u2010blog\/2018\/aml\u2010venetoclax\u2010azacitidine\u2010target\u2010leukemia\u2010stem\u2010cells"},{"key":"e_1_2_10_150_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07777-9"},{"key":"e_1_2_10_151_1","unstructured":"KarjalainenR PopaML LiuM et\u00a0al. Stroma\u2010derived factors stimulate JAK\/STAT signaling in AML cells resulting in resistance to BCL2 inhibitor venetoclax [poster]. In: european hematology association (EHA) 22nd congress; 2017 jun 22\u201325; madrid spain."},{"key":"e_1_2_10_152_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124453"},{"key":"e_1_2_10_153_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006343"},{"key":"e_1_2_10_154_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.214882"},{"key":"e_1_2_10_155_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34566"},{"key":"e_1_2_10_156_1","unstructured":"Beijing 302 Hospital. VA Combined With PD\u20101 Inhibitor for the Treatment of Relapsed and Refractory AML and High\u2010risk MDS [Internet]. ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US); 2024 Aug 5 [cited 2026 May 26]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT06536959"},{"key":"e_1_2_10_157_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007034"},{"key":"e_1_2_10_158_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-210370"},{"key":"e_1_2_10_159_1","unstructured":"National Cancer Institute (NCI). Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia [Internet]. ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US); 2020 Feb 20 [cited 2026 May 26]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT04277442"},{"key":"e_1_2_10_160_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2022.101036"},{"key":"e_1_2_10_161_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3665"},{"key":"e_1_2_10_162_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00674-5"},{"key":"e_1_2_10_163_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-651"},{"key":"e_1_2_10_164_1","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2021.125"},{"key":"e_1_2_10_165_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2024000540"},{"key":"e_1_2_10_166_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16061082"},{"key":"e_1_2_10_167_1","first-page":"9","volume-title":"Advances in Experimental Medicine and Biology","author":"Hadjis AD","year":"2025"},{"key":"e_1_2_10_168_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024247"},{"key":"e_1_2_10_169_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35806"},{"key":"e_1_2_10_170_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S191621"},{"key":"e_1_2_10_171_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35388"},{"key":"e_1_2_10_172_1","unstructured":"HeH. Reduced intensity allogeneic hematopoietic stem cell transplantation in comparison to consolidation therapy based venetoclax for elderly patients with acute myeloid leukemia after first CR [Internet]. ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US); 2024 Aug 26 [cited 2026 May 26]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT06571825"},{"key":"e_1_2_10_173_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1302356"},{"issue":"6","key":"e_1_2_10_174_1","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.3324\/haematol.2023.283790","article-title":"Multi\u2010gene measurable residual disease assessed by digital polymerase chain reaction has clinical and biological utility in acute myeloid leukemia patients receiving venetoclax\/azacitidine","volume":"109","author":"Winters AC","year":"2024","journal-title":"Haematologica"},{"key":"e_1_2_10_175_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217853"},{"key":"e_1_2_10_176_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-15272-9"},{"key":"e_1_2_10_177_1","doi-asserted-by":"publisher","DOI":"10.1080\/17501911.2025.2485019"},{"key":"e_1_2_10_178_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2025.06.002"},{"key":"e_1_2_10_179_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14051278"},{"key":"e_1_2_10_180_1","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2025.2512120"},{"key":"e_1_2_10_181_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-025-04111-z"}],"container-title":["Clinical and Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ctm2.70797","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ctm2.70797","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ctm2.70797","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T08:50:43Z","timestamp":1790326243000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ctm2.70797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":180,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1002\/ctm2.70797"],"URL":"https:\/\/doi.org\/10.1002\/ctm2.70797","archive":["Portico"],"relation":{},"ISSN":["2001-1326","2001-1326"],"issn-type":[{"value":"2001-1326","type":"print"},{"value":"2001-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"article-number":"e70797"}}